Can-Fite BioPharma American Depositary Shares
CANF
1 hedge funds and large institutions have $51K invested in Can-Fite BioPharma American Depositary Shares in 2013 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$40.1K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $44K | +$40.1K | +2 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $7K | – | – | – |
|
CANF Hedge Fund Activity: Q4 2013 in Review
1 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q4 2013, worth a combined $51K.
Buyers outnumbered sellers: 1 fund opened new CANF positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $40.1K.
- 1 institutional investor held Can-Fite BioPharma American Depositary Shares (CANF) as of Q4 2013, up from 0 in Q3 2013.
- Funds reported $51K of Can-Fite BioPharma American Depositary Shares stock for Q4 2013.
- 1 fund opened new Can-Fite BioPharma American Depositary Shares positions in Q4 2013 and 0 closed out, a net change of +1 holder.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q4 2013 was Morgan Stanley, an estimated $40.1K added.
Based on aggregated 13F filings for Q4 2013.